Table 1 Baseline characteristics of study patients with immune results, according to cohort.

From: Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

 

Epi700 CRC

Grampian CRC

P value (A)

S:CORT FOCUS

P value (B)

Pooled CRC

(n = 555)

(n = 578)

(n = 316)

(n = 1449)

Median age (interquartile range)

72 (64–78)

71 (62–78)

0.2938

64 (59–70)

<0.0001

70 (61–77)

Age

–

–

0.9010

–

<0.0001

–

<70

238 (42.88%)

251 (43.43%)

–

234 (74.05%)

–

723 (49.90%)

70+

317 (57.12%)

327 (56.57%)

–

82 (25.95%)

–

726 (50.10%)

Sex

–

–

0.3606

–

0.0023

–

Male

306 (55.14%)

302 (52.25%)

–

203 (64.24%)

–

811 (55.97%)

Female

249 (44.86%)

276 (47.75%)

–

113 (35.76%)

–

638 (44.03%)

Stage

–

–

0.0001

–

<0.0001

–

II

338 (60.90%)

285 (49.31%)

–

0 (0%)

–

623 (43.00%)

III

217 (39.10%)

293 (50.69%)

–

0 (0%)

–

510 (35.20%)

IV

0 (0.00%)

0 (0.00%)

–

316 (100%)

–

316 (21.81%)

MSI

–

–

<0.0001

–

<0.0001

–

Stable

392 (70.63%)

473 (81.83%)

–

273 (86.39%)

–

1138 (78.54%)

High

118 (21.26%)

97 (16.78%)

–

12 (3.80%)

–

227 (15.67%)

Missing

45 (8.11%)

8 (1.38%)

–

31 (9.81%)

–

84 (5.80%)

Adjuvant chemotherapy

–

–

<0.0001

–

<0.0001

–

No

401 (72.25%)

0 (0.00%)

–

0 (0.00%)

–

401 (27.67%)

Yes

154 (27.75%)

0 (0.00%)

–

316 (100.00%)

–

470 (32.44%)

Missing

0 (0.00%)

578 (100.00%)

–

0 (0.00%)

–

578 (39.89%)

  1. The data are presented as the number of patients (%). Differences in patient characteristics between the study cohorts for the stage-matched Epi700 and Grampian CRC in P value (A) and for all the cohorts in P value (B) using ANOVA and Pearson’s chi-squared test for continuous and categorical variables, respectively.
Back to article page